Phase 1 trial of recombinant human interleukin-1β (rhIL-1β), carboplatin, and etoposide in patients with solid cancers: Southwest oncology group study 8940

John Rinehart, Evan M Hersh, Brian Issell, Pierre Triozzi, William Buhles, James Neidhart

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Recombinant human interleukin-1β (rhIL-1β) was evaluated in a phase 1 clinical trial in which patients with metastatic or unresectable solid tumors received carboplatin and etoposide in cycle 1 and carboplatin, etoposide, and rhIL-1β in cycle 2. Recombinant hIL-1β was given intravenously for 5 days in one of three schedules: (1) immediately postchemotherapy, (2) delayed for 5 days after chemotherapy, or (3) concurrently with chemotherapy. Four dose levels of rhIL-1β were evaluated: 20, 50, 100, and 200 ng/kg. The doses of carboplatin and etoposide were not changed between cycle 1 and cycle 2 so that the effect of rhIL-1β on chemotherapy-induced hematotoxicity was evaluated; 54 patients were entered on study and 42 patients received at least two cycles of therapy and were thus evaluable for rhIL-1β toxicity and for the effect of rhIL-1β on hematotoxicity of carboplatin and etoposide. The major toxicities of rhIL-1β were chills, rigors, headache, fatigue, and hypotension. The maximum tolerated dose of rhIL-1β was not determined since the toxicities at all dose levels were similar. However, only 3/8 patients at the 200 ng/kg level received all 5 IL-1β infusions. We compared the effect of rhIL-1β on hematotoxicity of carboplatin/etoposide by comparing peripheral blood count parameters between cycles 1 and 2: rhIL-1β given postchemotherapy significantly increased absolute neutrophil count (AND) nadirs and improved neutrophil recovery times regardless of rhIL-1β dose level. Platelet count parameters were also improved when rhIL-1β was given postchemotherapy although these changes did not reach statistical significance. Thus, IL-1β exhibited extensive hematological effects but the usefulness of this agent in clinical practice will be limited by extensive toxicity at all tested dose levels.

Original languageEnglish (US)
Pages (from-to)403-410
Number of pages8
JournalCancer Investigation
Volume15
Issue number5
StatePublished - 1997

Fingerprint

Carboplatin
Etoposide
Interleukin-1
Neoplasms
Drug Therapy
Neutrophils
Chills
Clinical Trials, Phase I
Maximum Tolerated Dose
Platelet Count
Hypotension
Fatigue
Headache
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase 1 trial of recombinant human interleukin-1β (rhIL-1β), carboplatin, and etoposide in patients with solid cancers : Southwest oncology group study 8940. / Rinehart, John; Hersh, Evan M; Issell, Brian; Triozzi, Pierre; Buhles, William; Neidhart, James.

In: Cancer Investigation, Vol. 15, No. 5, 1997, p. 403-410.

Research output: Contribution to journalArticle

Rinehart, John ; Hersh, Evan M ; Issell, Brian ; Triozzi, Pierre ; Buhles, William ; Neidhart, James. / Phase 1 trial of recombinant human interleukin-1β (rhIL-1β), carboplatin, and etoposide in patients with solid cancers : Southwest oncology group study 8940. In: Cancer Investigation. 1997 ; Vol. 15, No. 5. pp. 403-410.
@article{0e3d5d21637648bfaf66139914eec884,
title = "Phase 1 trial of recombinant human interleukin-1β (rhIL-1β), carboplatin, and etoposide in patients with solid cancers: Southwest oncology group study 8940",
abstract = "Recombinant human interleukin-1β (rhIL-1β) was evaluated in a phase 1 clinical trial in which patients with metastatic or unresectable solid tumors received carboplatin and etoposide in cycle 1 and carboplatin, etoposide, and rhIL-1β in cycle 2. Recombinant hIL-1β was given intravenously for 5 days in one of three schedules: (1) immediately postchemotherapy, (2) delayed for 5 days after chemotherapy, or (3) concurrently with chemotherapy. Four dose levels of rhIL-1β were evaluated: 20, 50, 100, and 200 ng/kg. The doses of carboplatin and etoposide were not changed between cycle 1 and cycle 2 so that the effect of rhIL-1β on chemotherapy-induced hematotoxicity was evaluated; 54 patients were entered on study and 42 patients received at least two cycles of therapy and were thus evaluable for rhIL-1β toxicity and for the effect of rhIL-1β on hematotoxicity of carboplatin and etoposide. The major toxicities of rhIL-1β were chills, rigors, headache, fatigue, and hypotension. The maximum tolerated dose of rhIL-1β was not determined since the toxicities at all dose levels were similar. However, only 3/8 patients at the 200 ng/kg level received all 5 IL-1β infusions. We compared the effect of rhIL-1β on hematotoxicity of carboplatin/etoposide by comparing peripheral blood count parameters between cycles 1 and 2: rhIL-1β given postchemotherapy significantly increased absolute neutrophil count (AND) nadirs and improved neutrophil recovery times regardless of rhIL-1β dose level. Platelet count parameters were also improved when rhIL-1β was given postchemotherapy although these changes did not reach statistical significance. Thus, IL-1β exhibited extensive hematological effects but the usefulness of this agent in clinical practice will be limited by extensive toxicity at all tested dose levels.",
author = "John Rinehart and Hersh, {Evan M} and Brian Issell and Pierre Triozzi and William Buhles and James Neidhart",
year = "1997",
language = "English (US)",
volume = "15",
pages = "403--410",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Phase 1 trial of recombinant human interleukin-1β (rhIL-1β), carboplatin, and etoposide in patients with solid cancers

T2 - Southwest oncology group study 8940

AU - Rinehart, John

AU - Hersh, Evan M

AU - Issell, Brian

AU - Triozzi, Pierre

AU - Buhles, William

AU - Neidhart, James

PY - 1997

Y1 - 1997

N2 - Recombinant human interleukin-1β (rhIL-1β) was evaluated in a phase 1 clinical trial in which patients with metastatic or unresectable solid tumors received carboplatin and etoposide in cycle 1 and carboplatin, etoposide, and rhIL-1β in cycle 2. Recombinant hIL-1β was given intravenously for 5 days in one of three schedules: (1) immediately postchemotherapy, (2) delayed for 5 days after chemotherapy, or (3) concurrently with chemotherapy. Four dose levels of rhIL-1β were evaluated: 20, 50, 100, and 200 ng/kg. The doses of carboplatin and etoposide were not changed between cycle 1 and cycle 2 so that the effect of rhIL-1β on chemotherapy-induced hematotoxicity was evaluated; 54 patients were entered on study and 42 patients received at least two cycles of therapy and were thus evaluable for rhIL-1β toxicity and for the effect of rhIL-1β on hematotoxicity of carboplatin and etoposide. The major toxicities of rhIL-1β were chills, rigors, headache, fatigue, and hypotension. The maximum tolerated dose of rhIL-1β was not determined since the toxicities at all dose levels were similar. However, only 3/8 patients at the 200 ng/kg level received all 5 IL-1β infusions. We compared the effect of rhIL-1β on hematotoxicity of carboplatin/etoposide by comparing peripheral blood count parameters between cycles 1 and 2: rhIL-1β given postchemotherapy significantly increased absolute neutrophil count (AND) nadirs and improved neutrophil recovery times regardless of rhIL-1β dose level. Platelet count parameters were also improved when rhIL-1β was given postchemotherapy although these changes did not reach statistical significance. Thus, IL-1β exhibited extensive hematological effects but the usefulness of this agent in clinical practice will be limited by extensive toxicity at all tested dose levels.

AB - Recombinant human interleukin-1β (rhIL-1β) was evaluated in a phase 1 clinical trial in which patients with metastatic or unresectable solid tumors received carboplatin and etoposide in cycle 1 and carboplatin, etoposide, and rhIL-1β in cycle 2. Recombinant hIL-1β was given intravenously for 5 days in one of three schedules: (1) immediately postchemotherapy, (2) delayed for 5 days after chemotherapy, or (3) concurrently with chemotherapy. Four dose levels of rhIL-1β were evaluated: 20, 50, 100, and 200 ng/kg. The doses of carboplatin and etoposide were not changed between cycle 1 and cycle 2 so that the effect of rhIL-1β on chemotherapy-induced hematotoxicity was evaluated; 54 patients were entered on study and 42 patients received at least two cycles of therapy and were thus evaluable for rhIL-1β toxicity and for the effect of rhIL-1β on hematotoxicity of carboplatin and etoposide. The major toxicities of rhIL-1β were chills, rigors, headache, fatigue, and hypotension. The maximum tolerated dose of rhIL-1β was not determined since the toxicities at all dose levels were similar. However, only 3/8 patients at the 200 ng/kg level received all 5 IL-1β infusions. We compared the effect of rhIL-1β on hematotoxicity of carboplatin/etoposide by comparing peripheral blood count parameters between cycles 1 and 2: rhIL-1β given postchemotherapy significantly increased absolute neutrophil count (AND) nadirs and improved neutrophil recovery times regardless of rhIL-1β dose level. Platelet count parameters were also improved when rhIL-1β was given postchemotherapy although these changes did not reach statistical significance. Thus, IL-1β exhibited extensive hematological effects but the usefulness of this agent in clinical practice will be limited by extensive toxicity at all tested dose levels.

UR - http://www.scopus.com/inward/record.url?scp=0030766190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030766190&partnerID=8YFLogxK

M3 - Article

C2 - 9316621

AN - SCOPUS:0030766190

VL - 15

SP - 403

EP - 410

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 5

ER -